A randomised double-blind trial of diltiazem in the treatment of Raynaud's phenomenon (Q33555611)

28 July 2017

A randomised double-blind trial of diltiazem in the treatment of Raynaud's phenomenon (English)

1 reference

28 July 2017

Kahan A

1

1 reference

28 July 2017

Amor B

series ordinal

2

1 reference

28 July 2017

Menkes CJ

series ordinal

3

1 reference

28 July 2017

language of work or name

English

0 references

publication date

1 January 1985

1 reference

Annals of the Rheumatic Diseases

28 July 2017

1 reference

28 July 2017

44

1 reference

28 July 2017

1

1 reference

28 July 2017

30-33

1 reference

Morphologic changes in the digital arteries of patients with progressive systemic sclerosis (scleroderma) and Raynaud phenomenon.

28 July 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1001563

Biostatistics: how to detect, correct and prevent errors in the medical literature

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1001563

A prospective study of Raynaud phenomenon and early connective tissue disease. A five-year report

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1001563

Calcium channel blocking agents in the treatment of cardiovascular disorders. Part II: Hemodynamic effects and clinical applications

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1001563

Nifedipine as a therapeutic modality for Raynaud's phenomenon

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1001563

Mechanisms of vasodilation

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1001563

Mechanism of Action of Calcium-Channel-Blocking Agents

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1001563

Controlled study of nifedipine in the treatment of Raynaud's phenomenon

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1001563

Calcium Channel Blocking Agents in the Treatment of Cardiovascular Disorders. Part I: Basic and Clinical Electrophysiologic Effects

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1001563

Comparative pharmacology of calcium antagonists: Nifedipine, verapamil and diltiazem

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1001563

Cryodynamic hand angiography in the diagnosis and management of Raynaud's syndrome

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1001563

Blood hyperviscosity with reduced skin blood flow in scleroderma

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1001563

Raynaud's phenomenone: prospective study of 100 cases (author's transl)

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1001563

Immune complexes in peripheral blood polymorphonuclear leucocytes of patients with Raynaud's phenomenon

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1001563

Drug therapy: vasodilator drugs in peripheral vascular disease

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1001563

The importance of beta, the type II error and sample size in the design and interpretation of the randomized control trial. Survey of 71 "negative" trials

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1001563

Sample size nomograms for interpreting negative clinical studies

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1001563

Controlled trial of nifedipine in the treatment of Raynaud's phenomenon

31 October 2018

1 reference

12 December 2020

DNA probes in X-linked disease

1 reference

12 December 2020

Controlled Double-Blind Trial of Nifedipine in the Treatment of Raynaud's Phenomenon

1 reference

12 December 2020

Effects of Diltiazem Hydrochloride on Embryonic Development: Species Differences in the Susceptibility and Stage Specificity in Mice, Rats, and Rabbits

1 reference

12 December 2020

Pathophysiology of Raynaud's disease

1 reference

12 December 2020

1 reference

12 December 2020

Calcium channel blockers and Raynaud's disease

1 reference

12 December 2020

The treatment of severe Raynaud's phenomenon with verapamil

1 reference

12 December 2020

Diltiazem and Raynaud's syndrome

1 reference

12 December 2020

Identifiers

DOI

10.1136/ARD.44.1.30

1 reference

28 July 2017

1 reference

28 July 2017

1 reference